Tag: Cenobamate

While about 70% of patients with epilepsy achieve seizure control with one to three antiseizure medications (ASMs), many still experience adverse effects or have drug-resistant epilepsy, necessitating the development of newer treatments. The latest therapies, known as new generation antiseizure drugs, offer unique mechanisms and improved safety profiles to address these challenges.

As of late 2025, there is no generic version of the antiepileptic drug Xcopri (cenobamate) available in the United States. This means patients prescribed this medication must obtain the higher-cost brand-name drug, a situation that often leads to questions about affordability and future options for a generic form of Xcopri.

Approximately one-third of epilepsy patients are resistant to older anti-seizure medications, driving the development of new treatments with novel mechanisms and better side-effect profiles. Exploring **what are the new seizure medications** reveals significant advancements that offer renewed hope for improved seizure control and quality of life.